Illumina Inc. (ILMN) has reported significant growth driven by strong demand in clinical markets, with sequencing consumables revenue rising 20% YoY, excluding China, in the first quarter of 2026. The company installed over 80 NovaSeq X units during the same period, exceeding previous targets. Illumina anticipates 2026 revenues between $4.52 billion and $4.62 billion, with expected non-GAAP diluted EPS ranging from $5.15 to $5.30.
Despite a market capitalization of $21.41 billion and a 68.3% stock surge over the last year, the company faces challenges from constrained demand in China, with revenues dropping 27.8% to $52 million. Macroeconomic pressures, including tariffs and inflation, are also impacting margins and demand, with an operating margin expected to be around 22% in the next quarter.
The Zacks Consensus Estimate for Illumina’s 2026 EPS has increased by 1.2% to $5.18, while revenue estimates stand at $4.56 billion, indicating a 5.1% rise from the previous year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
